




The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program (BMSF DCTCDP) Informational Webinar

Winter 2021/2022





Welcome and Agenda

Introduction

- Catharine Grimes, MBA: Senior Director, Bristol Myers Squibb Foundation (BMSF)
- Joy L. Jones, PhD: Chief Program Officer, National Medical Fellowships (NMF)
- Sybol Anderson, PhD: Director, Diversity in Research Programs, National Medical Fellowships (NMF)

Program Vision

- Robert A. Winn, MD: Director, Virginia Commonwealth University (VCU) Massey Cancer Center; Senior Associate Dean for Cancer Innovation; Professor, Division of Pulmonary Disease and Critical Care Medicine, VCU; Chair, BMSF DCTCDP National Advisory Committee (NAC)

Program Overview

- Catharine Grimes, MBA
- Joy L. Jones, PhD
- Sybol Anderson, PhD



Bristol Myers Squibb™ Foundation

Mission: To improve health outcomes and reduce health disparities for underserved populations.

Vision: A world where everyone has equitable access to high quality health care.



NMF's mission is to provide scholarships and support for students underrepresented in medicine and the health professions.

NMF's vision is to empower and support aspiring physicians and health professionals underrepresented in medicine to contribute to the health of our nation.

We envision a diverse healthcare workforce which will have the leadership, commitment and cultural competency to achieve health equity.



Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program

Catharine Grimes, MBA

Senior Director, BMSF

Joy L. Jones, PhD

Chief Program Officer, NMF

The Need for Diversity in Clinical Trials

Definition of Diversity in Clinical Trials

- Engage a patient population that mirrors the epidemiology of the disease studied
- Assure the ecosystem around the trial reflects diverse populations being served (e.g., includes research sites, principal investigators, and extended care teams)
- Design in inclusivity from start

Benefits of Diversity in Clinical Trials

- Better Science. Safety and efficacy of new medicines should be assessed in the patients with the condition
- Personalized Medicine. Understanding the range of different responses to treatments based on genetic variations
- Data. Better inform treatment decisions by making new options available to patients
- Address disparity and inequity.

Current State of Clinical Trials

- Black Americans represent 13% of the US population but reflect only about 4% of participants in clinical trials
- Hispanics represent 16% of the US population but only about 3% of clinical trial participants
- In general, 80% of patients taking part in clinical trials are white*

*CDC Heart Disease Facts
<https://www.cdc.gov/heartdisease/facts.htm>



BMSF Diversity in Clinical Trials Career Development Program



Goals

- To transform the clinical research landscape by building and strengthening partnerships between clinical investigators and the communities where their patients reside.
- To facilitate an approach to clinical and translational research that is community-informed, designed and conducted.

Approach

- Provide training and resources to build a network of URM clinical investigators with community engagement and research skills.
- Expand the number of community-based sites with the capacity to conduct clinical and translational research.







Outcome

- Increased participation of diverse patients in clinical and translational research.

Impact

- Improved public health through an increase in the development of new drugs, vaccines, and therapeutic products that are effective in all populations.

Key Program Elements

 Commitment	<ul style="list-style-type: none">• To develop and train 250 new clinical investigators dedicated to increasing diversity in clinical trials (~50/year)• Provide immersive community-based experiences in clinical trial research to 250 medical students underrepresented in medicine• To increase diversity in clinical trial sites through a clinical trial site development infrastructure fund
 Award	<p>\$120K/year for 2 years: Require at least 40% of Scholar's time</p>
 Mentoring	<p>Scholar will be mentored by a Principal Investigator at an established clinical trial site and will substantively participate in the PI's active clinical trial</p>
 Training	<p>Scholars will receive training in both: methods of clinical research (including investigator-initiated and industry-sponsored clinical trials), and in community outreach and engagement processes and methods.</p> <ul style="list-style-type: none">• A 6-Day Intensive led by AACR: Design and Implementation of Clinical Trials, a Companion Workshop to the BMSF DCTCDP• A 2-Year Community-Oriented Clinical Trialist curriculum with bi-weekly lectures by distinguished visiting faculty
 Pipeline program	<p>Scholar will serve as a mentor to an URM medical student during the 2nd program year. 250 URM medical students (50/year) will participate in a 6-week summer immersion program learning the basics of clinical trials and working in underserved community health settings to provide outreach, education and engagement on clinical trials</p>
 Infrastructure fund	<p>There will be an infrastructure fund that graduates of the program can tap into in order to build capacity and stand-up clinical trials sites in communities with diverse and heavily burdened patient populations</p>

Candidate Eligibility Criteria



Candidate Profile

Eligible candidates will reflect the National Science Foundation (NSF) definition of underrepresented populations in the US Biomedical, Clinical, Behavioral and Social Sciences Research Enterprise:

- African Americans or Blacks
- Hispanics or Latinos
- American Indians or Alaska Natives
- Native Hawaiians or Other Pacific Islanders

OR have a demonstrated commitment to increasing diverse patient participation in clinical trials



Citizenship or Immigration Status

Eligible candidates will be **US Citizens or Lawful Permanent Residents (LPRs)** as defined by the [US Department of Homeland Security](#). **O-1 & H-1B Visa holders are eligible; the visa must be valid during the full program period.**



Professional Degree

Eligible candidates will hold the degree of **MD, MD/PhD, DO or DO/PhD**




Career Phase

Early-Stage Investigator (ESI): As defined by NIH, a new investigator who has completed his or her terminal research degree or medical residency - whichever date is later - within the past 10 years and **has not yet** competed successfully for a substantial, competing NIH research grant (Applicants with RO1 or RO1 equivalent are ineligible).



BMSF DCTCDP: Timeline*



**Dates are subject to change*



How to Apply to the BMSF DCTCDP

Sybol Anderson, PhD

Director, Diversity in Research Programs, NMF



Application Process with Key Target Dates

The BMSF DCTCDP application has two steps, which includes:

- 1) submission of a [Letter of Intent \(LOI\)](#), and
- 2) by invitation, submission of a **full Application**

Letter of Intent Phase	Oct. 18, 2021 - Jan. 14, 2022
Full Application Phase	Jan. 31 - Apr. 29, 2022
Selection Process	May 2 - Jul. 31, 2022
Scholar Award Notification	Aug. 2022
Selection Announcement	Oct. 2022
Second Cohort Begins	Oct. 2022

Note: Dates are subject to change.



Letter of Intent - Step 1

- Degree Information
- Clinical Specialty
- Demographic Information
- Citizenship/Immigration Status
- Employment Information
- Institutional Support
- Identification of Mentor
- Current Sources of Funding
- Publications within the last 2-3 years
- Current CV
- Essay Question #1: Commitment to promoting diversity in clinical trials throughout career and how this program can advance abilities in doing so.
- Essay Question # 2: Experience with clinical trial design and/or participation.
- Essay Question #3: Research aspired to participate in during this program and ideas for increasing engagement of diverse patients.

BMSF DCTCDP National Advisory Committee



Robert Winn, MD (Chair)

Director, Massey Cancer Center | Senior Associate Dean for Cancer Innovation | Professor, Division of Pulmonary Disease & Critical Care Medicine, Virginia Commonwealth University



Roy S. Herbst, MD, PhD

Ensign Professor of Medicine | Professor of Pharmacology | Chief of Medical Oncology | Director, Thoracic Oncology Research Program | Associate Director for Translational Research | Yale Comprehensive Cancer Center | Yale School of Medicine



Nancy Daly, RN, MS, MPM

Executive Vice President & CEO, Conquer Cancer & the ASCO Foundation



Leon Bernal-Mizrachi, MD

Associate Professor, Dept of Hematology & Medical Oncology | Service Chief, Hematology & Medical Oncology | Associate Director, Hematology & Medical Oncology | Fellowships Program | Emory University School of Medicine & Grady Health Systems



Gail Kerr, MD, FRCP

Professor of Medicine & Chief of Rheumatology at Howard University Hospital & Howard University



Lori Pierce, MD

Professor, Department of Radiation Oncology | Vice Provost for Academic & Faculty Affairs, Michigan Medicine, University of Michigan



Edith Mitchell, MD, MACP, FCPP

Clinical Professor of Medicine & Medical Oncology | Director, Center to Eliminate Cancer Disparities | Associate Director, Diversity Affairs | Sidney Kimmel Cancer Center at Jefferson Health



Karen Winkfield, MD, PhD

Executive Director, Meharry-Vanderbilt Alliance, Radiation Oncologist, Vanderbilt University Medical Center



Eliseo J. Perez-Stable, MD

Director, National Institute on Minority Health & Health Disparities | National Institutes of Health | Internal Medicine



José López, MD

Chief Scientific Officer & Full Member | Blood Works Northwest Research Institute | Professor of Medicine, Division of Hematology, University of Washington School of Medicine



Lucio Miele, MD, PhD

Professor & Dept. Head, LSU School of Med., Dept. of Genetics | Director, Inter-Institutional Programs, LSU Stanley | Scott Cancer Ctr. & Louisiana Cancer Research Consortium | Cancer Crusaders Endowed Professor in Cancer Research | Louisiana State Uni. Health Sciences Ctr.



Kathryn Owen, Vice President

Head of Global Development Operations Bristol Myers Squibb




Ruben Mesa, MD, FACP

Presidential Chair, Mays Family Foundation | Distinguished University | Director, Mays Cancer Center | Professor of Medicine, UT Health San Antonio MD Anderson



Brian Rivers, PhD, MPH

Director, Cancer Health Equity Institute, National Center for Primary Care Morehouse School of Medicine



Amelie G. Ramirez, DrPH, MPH

Director & Professor, Institute for Health Promotion Research, Graduate School of Biomedical Sciences, UT Health San Antonio | Dept. of Population Health Sciences, Chair | MCC Associate Director for Community Outreach & Engagement



Annabelle Volgman, MD, FACC, FAHA

McMullan-Eybel Chair of Excellence in Clinical Cardiology | Professor of Medicine, Rush College of Medicine | Medical Director, Rush Heart Center for Women Rush University



Winston Wong, MD, MS, FAAFP

Scholar-in-Residence, UCLA Kaiser Permanente Center for Equity | UCLA Fielding School of Public Health



Hannah Valentine, MD

Professor, Cardiovascular Medicine Stanford University Medical Center | Prior: Chief Officer for Scientific Workforce Diversity, National Institutes of Health



QUESTIONS

Thank you for your interest in the BMSF DCTCDP!

Letter of Intent link:



Direct inquiries to: DCTCDPinfo@nmfonline.org

Program website: www.diversityinclinicaltrials.org